Go to the NICE website to read the FAD on dasatinib/nilotinib and imatinib for first line therapy in CML.
Needless to say as we expected.
We will post our official statement this evening.
http://guidance.nice.org.uk/TA/Wave24/15/FAD/FinalAppraisalDetermination/pdf/English
It is, as suspected, but until you see it in black and white, it doesn't hit home! For me, dasatinib has been the 'wonder drug'. I take two 50mg tablets once a day - either with or without food - how easy is that?! It's almost 3 years since my diagnosis and I now have the best PCR's I have had in all that time with very few side effects - and this is because of dasatinib. I'm saddened to think that newly diagnosed patients may never get this opportunity.
Dear Rachael,
I agree, before any FAD there is always hope, even though we suspect that there will be a negative outcome. Of course it is good news for those who would respond better to nilotinib 1st line as this will be an available option along with imatinib 400mg. However, as you have rightly said, dasatinib for some people is the better option and as in your case is very well tolerated as well as highly effective.
I have just uploaded CMLS groups statement on the home page which lays out our view of the FAD. We will of course be considering whether we will have grounds for appeal over the next few days. We still hope that BMS will consider offering a PAS to the DH, but we have no way of knowing if they are considering this as an option.
I share your disappointment,
Sandy
